- Acumen Powered by Robins Kaplan LLP®
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
June 17, 2024Emily Tremblay Named IP Rising Star by Euromoney in 2024 Women in Business Law Awards
-
June 17, 2024Three Robins Kaplan Partners Named BTI Client Service All-Stars
-
June 13, 2024Brendan Johnson Named South Dakota Trial Lawyer of The Year
-
June 27, 2024Sex Abuse Litigation
-
June 10-11, 20242024 Probate and Trust Law Section Conference
-
June 11, 2024FBA 2024 Federal Practice Seminar
-
June 2024Robins Kaplan Secures Landmark $7.75 Million Verdict in Aerosol Duster Misuse Case
-
June 2024To Seize or Not to Seize: Campus Protests and Police Uses of Force
-
June 2024Communicating Your Estate Plan: A Helpful Tool, Not a Fix-All
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Reached Settlement Worth Up to $28 Million Against Martin Shkreli and His Former Companies for Alleged Monopolization of Life-Saving Drug Daraprim
Settlement Enjoins Defendants’ Anticompetitive Conduct and Bars Shkreli from the Pharmaceutical Industry for Life
June 17, 2022
BCBSM, Inc. v. Vyera Pharmaceuticals, LLC et al.
On January 31, 2022, as court-appointed interim lead counsel, Robins Kaplan reached a settlement worth up to $28 million on behalf of indirect purchasers alleging that Martin Shkreli and his former companies illegally monopolized the market for Daraprim—a once-affordable, life-saving drug that increased in price by more than 4,000 percent under Shkreli’s leadership.
In March of 2021, Robins Kaplan filed the first—and only—private lawsuit in the country against Martin Shkreli and his former companies Vyera Pharmaceuticals and Phoenixus AG, as well as Vyera’s former CEO Kevin Mulleady. The firm filed suit on behalf of Blue Cross Blue Shield of Minnesota and a proposed class of health plans that purchased or provided reimbursement for Daraprim, the gold-standard treatment for toxoplasmosis, a parasitic infection that can be fatal for people with compromised immune systems, like those with HIV/AIDS. Plaintiffs alleged that defendants endangered vulnerable patients and overcharged health plans by raising the price of Daraprim from $17.50 to $750 per pill while illegally blocking lower-cost generic versions.
The settlement, approved in June of 2022, provides up to $28 million for third-party payors who were allegedly overcharged because of defendants’ scheme, enjoins defendants’ anticompetitive conduct, and bars Shkreli from the pharmaceutical industry for life.
Related Professionals
Ben Steinberg
Partner
Similar Results
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.